TABLE 2.

CYP2D6-guided dosing recommendations for risperidone across DPWG, FDA, and CPIC frameworks.

Guidelines	Adjustment for PM (poor metabolizers)	Adjustment for UM (ultrarapid metabolizers)
DPWG	Yes (33%–50% dose reduction)	Yes (alternative drug or titration based on active metabolite)
FDA	No (standard clinical adjustment)	Not explicitly mentioned in label
CPIC	In development (Provisional Level B)	In development (Provisional Level B)

The table compares guidance from the Dutch Pharmacogenetics Working Group (DPWG), the U.S., Food and Drug Administration (FDA) labeling, and the Clinical Pharmacogenetics Implementation Consortium (CPIC) regarding dose adjustment in poor metabolizers (PM) and ultrarapid metabolizers (UM).